A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19

Date Added
August 12th, 2020
PRO Number
Pro00102540
Researcher
Gary Headden

List of Studies


Keywords
COVID-19, Coronavirus, Vaccine
Summary

The purpose of this study is to see if a vaccine that is being developed to prevent people from getting sick with COVID-19 is safe and effective and also to see how well it is tolerated. Participants will receive a shot of either the vaccine or a placebo twice: once on Day 1 and a booster shot on Day 29. Participants will have blood drawn several times for the next 24 months to assess your immune system's (how your body fights off the virus) response. Participation will last about 24 months. Participants will receive payment in return for their time and effort.

Institution
MUSC
Recruitment Contact
Nadine O'Connor
843-792-6890
covidvaccine@musc.edu

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated heart failure (INVESTED)

Date Added
October 18th, 2016
PRO Number
Pro00059616
Researcher
Bhavadharini Ramu

List of Studies


Keywords
Cardiovascular, Heart, Vaccine
Summary

INVESTED is a multi-site trial comparing high-dose (60 μg per vaccine viral strain) trivalent influenza vaccine to standard-dose (15 μg per viral strain) quadrivalent influenza vaccination for up to three influenza seasons in high-risk cardiovascular disease patients with a history of myocardial infarction in the previous 12 months OR history of heart failure hospitalization in the previous 24 months. Subjects will be randomly assigned to receive either the high-dose or standard-dose vaccine.

Institution
MUSC
Recruitment Contact
Ricardo Cantu
843-792-8894
cantur@musc.edu



-- OR --